Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14810543 | 0.88 | GAA (0.52) | FAAH | |
| SCHEMBL14099923 | 0.88 | — | — | |
| SCHEMBL18344207 | 0.88 | — | — | |
| SCHEMBL18344219 | 0.86 | — | — | |
| SCHEMBL18344030 | 0.85 | — | — | |
| SCHEMBL3354226 | 0.84 | — | — | |
| SCHEMBL18344059 | 0.84 | — | — | |
| SCHEMBL28473715 | 0.83 | FAAH (0.60) | FAAH | |
| SCHEMBL18344058 | 0.83 | — | — | |
| SCHEMBL18344008 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107743483-B | NADPH oxidase 4 inhibitors | 埃科特莱茵药品有限公司 | 2022-01-28 | — | — | CN | claimed |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELTION PHARMACEUTICALS LTD (CH) | 2021-12-23 | — | — | US | claimed |
| EP-3310767-B1 | 2,5-DISUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AS NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-07-22 | — | — | EP | claimed |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-05-28 | — | — | US | claimed |
| US-10584118-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2020-03-10 | — | — | US | claimed |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-28 | — | — | US | claimed |
| EP-3310767-A1 | NADPH OXIDASE 4 INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2018-04-25 | — | — | EP | claimed |
| WO-2016207785-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-29 | — | — | WO | claimed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| EP-4737445-A1 | NOVEL SATURATED HETEROCYCLE-SUBSTITUTED HETEROARYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025005367-A1 | NOVEL SATURATED HETEROCYCLE-SUBSTITUTED HETEROARYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | 한국과학기술연구원 | 2025-01-02 | — | — | WO | disclosed |
| US-20230391774-A1 | Novel Compounds | AC IMMUNE SA (CH) | 2023-12-07 | — | — | US | disclosed |
| EP-4229052-A1 | NOVEL COMPOUNDS | AC Immune SA (CH) | 2023-08-23 | — | — | EP | disclosed |
| CN-116568684-A | Novel compounds | AC免疫有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | FAAH 3811/4885 |
| US-10584118-B2 | NADPH oxidase 4 inhibitors | NOX4, NOX1, CYBB | FAAH 4198/4885 |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | FAAH 4198/4885 |
| US-20230391774-A1 | Novel Compounds | MAPT, PSEN2, PSEN1 | FAAH 4118/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | FAAH 4513/4885 |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | FAAH 4198/4885 |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | FAAH 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.